Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test [Seeking Alpha]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Seeking Alpha
The phase 1b data in atopic dermatitis show promise, and a 400-patient phase 2 study in that indication will allow NKTR to examine if the drug indeed has value. I give the phase 2 atopic dermatitis study a good chance of success, but there will be a comparison to approved competitors. NKTR has a catalyst in 2024 from another pipeline member, NKTR-255, with interim data from the Javelin Bladder Medley study expected in H2'24. Nektar Therapeutics ( NASDAQ: NKTR ) has an interesting drug in its pipeline, rezpegaldesleukin (rezpeg), that has the potential to treat inflammation in a new way. The company is underway on a large study in atopic dermatitis, and recently announced it had initiated enrollment in another study in alopecia areata. This article takes a look at that data, the trial design and the timeline of readouts. Rezpeg stimulates regulatory T Cells Rezpeg is a modified form of interleukin-2 (IL-2) designed to activate the IL-2 receptor found on regulatory T-cells (w
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]Yahoo! Finance
- Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference [Yahoo! Finance]Yahoo! Finance
- Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferencePR Newswire
- Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics (NASDAQ: NKTR) had its price target raised by analysts at Jefferies Financial Group Inc. from $0.50 to $1.00. They now have a "hold" rating on the stock.MarketBeat
NKTR
Earnings
- 3/4/24 - Miss
NKTR
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/17/24 - Form 8-K
- NKTR's page on the SEC website